BioCorRx Inc. (OTCMKTS:BICX – Get Free Report) was the target of a significant increase in short interest in April. As of April 15th, there was short interest totalling 800 shares, an increase of 100.0% from the March 31st total of 400 shares. Based on an average daily volume of 2,800 shares, the short-interest ratio is presently 0.3 days.
BioCorRx Trading Down 8.5 %
Shares of BioCorRx stock traded down $0.07 during midday trading on Friday, reaching $0.75. The company had a trading volume of 902 shares, compared to its average volume of 1,508. The company has a market capitalization of $6.67 million, a price-to-earnings ratio of -1.67 and a beta of 0.59. The stock has a fifty day simple moving average of $1.02 and a 200 day simple moving average of $1.07. BioCorRx has a 1-year low of $0.67 and a 1-year high of $2.22.
BioCorRx (OTCMKTS:BICX – Get Free Report) last issued its quarterly earnings results on Monday, April 1st. The company reported ($0.11) earnings per share for the quarter. The company had revenue of $0.02 million for the quarter.
BioCorRx Company Profile
BioCorRx Inc, through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders in the United States. It distributes and licenses BioCorRx recovery program, a non-addictive and medication-assisted treatment program that includes a counseling program coupled with its proprietary naltrexone implant; and distributes UnCraveRx weight loss management program, a medically assisted weight management program to reduce food cravings combined with on-demand virtual lifestyle support, fitness, and nutrition.
Further Reading
- Five stocks we like better than BioCorRx
- 3 REITs to Buy and Hold for the Long Term
- MarketBeat Week in Review – 4/22 – 4/26
- How to Calculate Retirement Income: MarketBeat’s Calculator
- 3 Stocks Leading the U.S. Agriculture Comeback
- Quiet Period Expirations Explained
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for BioCorRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCorRx and related companies with MarketBeat.com's FREE daily email newsletter.